Type of Publication: | Journal article |
Publication status: | Published |
URI (citable link): | http://nbn-resolving.de/urn:nbn:de:bsz:352-2-1vc2qm7jgams93 |
Author: | Amelio, Ivano; Gostev, Mikhail; Knight, Richard A.; Willis, Anne E.; Melino, Gerry; Antonov, Alexey V. |
Year of publication: | 2014 |
Published in: | Cell death & disease ; 5 (2014). - e1051. - Nature Publishing Group. - eISSN 2041-4889 |
Pubmed ID: | 24503543 |
DOI (citable link): | https://dx.doi.org/10.1038/cddis.2014.9 |
Summary: |
The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any independent verification that the observed effects in vitro may be valid in a clinical setting, and that the drug could potentially affect patient survival in vivo is of paramount importance. Despite considerable recent efforts in computational drug repositioning, none of the studies have considered patient survival information in modelling the potential of existing/new drugs in the management of cancer. Therefore, we have developed DRUGSURV; this is the first computational tool to estimate the potential effects of a drug using patient survival information derived from clinical cancer expression data sets. DRUGSURV provides statistical evidence that a drug can affect survival outcome in particular clinical conditions to justify further investigation of the drug anticancer potential and to guide clinical trial design. DRUGSURV covers both approved drugs (∼1700) as well as experimental drugs (∼5000) and is freely available at http://www.bioprofiling.de/drugsurv.
|
Subject (DDC): | 570 Biosciences, Biology |
Keywords: | drug repositioning, clinical trial design, patient survival, thioridazine |
Link to License: | In Copyright |
Refereed: | Yes |
AMELIO, Ivano, Mikhail GOSTEV, Richard A. KNIGHT, Anne E. WILLIS, Gerry MELINO, Alexey V. ANTONOV, 2014. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. In: Cell death & disease. Nature Publishing Group. 5, e1051. eISSN 2041-4889. Available under: doi: 10.1038/cddis.2014.9
@article{Amelio2014-02-06DRUGS-57119, title={DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information}, year={2014}, doi={10.1038/cddis.2014.9}, volume={5}, journal={Cell death & disease}, author={Amelio, Ivano and Gostev, Mikhail and Knight, Richard A. and Willis, Anne E. and Melino, Gerry and Antonov, Alexey V.}, note={Article Number: e1051} }
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/57119"> <dc:creator>Gostev, Mikhail</dc:creator> <dc:rights>terms-of-use</dc:rights> <dcterms:abstract xml:lang="eng">The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any independent verification that the observed effects in vitro may be valid in a clinical setting, and that the drug could potentially affect patient survival in vivo is of paramount importance. Despite considerable recent efforts in computational drug repositioning, none of the studies have considered patient survival information in modelling the potential of existing/new drugs in the management of cancer. Therefore, we have developed DRUGSURV; this is the first computational tool to estimate the potential effects of a drug using patient survival information derived from clinical cancer expression data sets. DRUGSURV provides statistical evidence that a drug can affect survival outcome in particular clinical conditions to justify further investigation of the drug anticancer potential and to guide clinical trial design. DRUGSURV covers both approved drugs (∼1700) as well as experimental drugs (∼5000) and is freely available at http://www.bioprofiling.de/drugsurv.</dcterms:abstract> <dc:contributor>Melino, Gerry</dc:contributor> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/57119"/> <dc:contributor>Antonov, Alexey V.</dc:contributor> <dc:creator>Amelio, Ivano</dc:creator> <dc:creator>Melino, Gerry</dc:creator> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/57119/3/Amelio_2-1vc2qm7jgams93.pdf"/> <dc:creator>Willis, Anne E.</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/57119/3/Amelio_2-1vc2qm7jgams93.pdf"/> <dcterms:title>DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information</dcterms:title> <dc:language>eng</dc:language> <dc:contributor>Knight, Richard A.</dc:contributor> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:creator>Knight, Richard A.</dc:creator> <dc:creator>Antonov, Alexey V.</dc:creator> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-03-31T12:59:57Z</dc:date> <dc:contributor>Gostev, Mikhail</dc:contributor> <dc:contributor>Willis, Anne E.</dc:contributor> <dc:contributor>Amelio, Ivano</dc:contributor> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-03-31T12:59:57Z</dcterms:available> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> <dcterms:issued>2014-02-06</dcterms:issued> </rdf:Description> </rdf:RDF>
Amelio_2-1vc2qm7jgams93.pdf | 22 |